Results
22
Companies with strong growth potential, backed by optimistic outlooks both from analysts and management.
22 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
ADOC | €5.89 | 1.9% | -51.2% | €88.6m | €6.30 | PS14.6x | E63.0% | n/a | Pharmaceuticals & Biotech | ||
ALOKW | €12.30 | -3.5% | -42.5% | €101.6m | €20.75 | PE13.4x | E36.0% | n/a | Capital Goods | ||
VU | €140.20 | 3.5% | 30.5% | €2.2b | €193.33 | PE28.2x | E25.7% | 0.2% | Tech | ||
OSE | €8.18 | 13.5% | 119.9% | €177.9m | €11.43 | PS79.9x | E5.9% | n/a | Pharmaceuticals & Biotech | ||
FDE | €27.05 | -5.6% | -35.6% | €142.8m | €60.33 | PE18.2x | E31.9% | n/a | Energy | ||
ALMUN | €0.47 | 11.8% | -79.5% | €4.2m | €1.30 | PB0.3x | E149.2% | n/a | Tech | ||
ALICA | €9.86 | -1.4% | -29.6% | €79.7m | €16.00 | PE14.5x | E35.1% | 2.0% | Tech | ||
ALCUR | €6.18 | -1.0% | 166.4% | €35.6m | €8.48 | PE19.8x | E27.5% | n/a | Capital Goods | ||
MEDCL | €18.08 | 0.3% | 166.3% | €525.9m | €22.03 | PS44x | E93.9% | n/a | Pharmaceuticals & Biotech | ||
ALSMA | €4.18 | 2.7% | 69.9% | €21.8m | €5.80 | PE20.6x | E35.2% | n/a | Healthcare | ||
ALSTI | €18.10 | 0% | n/a | €92.0m | €16.50 | PE46x | E28.5% | 1.0% | Capital Goods | ||
ALLIX | €7.91 | 5.5% | -23.9% | €51.9m | €13.50 | PS1.6x | E102.1% | n/a | Software | ||
ALECP | €0.60 | 50.0% | -16.0% | €73.8m | n/a | PE82x | E86.8% | 0% | Media | ||
ALVGO | €3.09 | -2.8% | -13.0% | €18.8m | €4.40 | PS1.5x | E77.2% | n/a | Software | ||
ALHOP | €22.80 | -1.7% | 33.3% | €65.5m | €30.40 | PE14.3x | E22.3% | 2.9% | Media | ||
ALCIS | €8.74 | 1.4% | -4.6% | €68.1m | €12.10 | PE21.3x | E56.8% | 1.9% | Commercial Services | ||
OVH | €6.15 | 1.2% | -33.5% | €1.2b | €9.35 | PS1.2x | E101.1% | n/a | Software | ||
LSS | €28.20 | 1.8% | -4.4% | €1.1b | €34.58 | PE33.4x | E29.3% | 1.3% | Software | ||
GUI | €5.72 | 2.5% | -16.3% | €86.0m | €7.85 | PE89.2x | E55.2% | 0% | Tech | ||
CLA | €1.46 | -1.1% | -13.9% | €83.1m | €4.65 | PE-16.6x | E88.7% | n/a | Software | ||
ALPAT | €15.60 | 0% | 20.0% | €17.2m | €11.50 | n/a | E92.7% | n/a | Pharmaceuticals & Biotech | ||
EXN | €23.40 | 1.1% | 24.2% | €2.1b | €25.33 | PE51.6x | E33.7% | 0% | Software |